The webinar will feature presentations from Key Opinion Leaders (KOL’s) Benjamin Besse, MD (Institut Gustave Roussy, Villejuif, France) and Jacob Sands, MD (Dana-Farber Cancer Institute, Boston) who will discuss the current treatment landscape and unmet medical need in treating patients with small cell lung cancer.

PharmaMar’s potential treatment solution, Zepzelca® (lurbinectedin), will be discussed. Zepzelca® (lurbinectedin) selectively inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

A live question and answer session will follow.